Epelbaum J, Javoy-Agid F, Enjalbert A, Krantic S, Kordon C, Agid Y
INSERM, U. 159, Unité de Neuroendocrinologie, Centre Paul Broca, Paris, France.
J Neurol Sci. 1988 Nov;87(2-3):167-74. doi: 10.1016/0022-510x(88)90242-0.
Somatostatin (SRIF) binding sites were characterized in membrane preparations from post mortem human brain tissues using 125I-Tyr0-D-Trp8-SRIF as a ligand. Density of binding sites were high in subiculum and cortex, moderate in temporal cortex, hippocampal formation and hypothalamus and low in putamen. No correlation was observed with the regional distribution of SRIF levels as measured by RIA. Pharmacological characterization, in frontal cortex preparations, revealed that 125I-Tyr0-D-Trp8-SRIF binding was heterogenous and fitted best with a two sites model. 125I-Tyr0-D-Trp8-SRIF binding was guanine nucleotide dependent. Cortical 125I-Tyr0-D-Trp-8-SRIF binding was not different from controls in non-demented or demented parkinsonians and in patients with progressive supranuclear palsy. On the contrary, SRIF levels were significantly decreased in demented parkinsonians.
使用125I-Tyr0-D-Trp8-生长抑素(SRIF)作为配体,对取自死后人类脑组织的膜制剂中的生长抑素(SRIF)结合位点进行了表征。结合位点密度在海马下托和皮质中较高,在颞叶皮质、海马结构和下丘脑中中等,在壳核中较低。未观察到与通过放射免疫分析测定的SRIF水平的区域分布存在相关性。在额叶皮质制剂中的药理学表征显示,125I-Tyr0-D-Trp8-SRIF结合是异质性的,最适合双位点模型。125I-Tyr0-D-Trp8-SRIF结合是鸟嘌呤核苷酸依赖性的。在非痴呆或痴呆帕金森病患者以及进行性核上性麻痹患者中,皮质125I-Tyr0-D-Trp-8-SRIF结合与对照无差异。相反,痴呆帕金森病患者的SRIF水平显著降低。